From OpenWetWare

Jump to: navigation, search

Click here for Dr. Licht's PubMed listing

Back to Main Page Jonathan Licht's Lab Original Reports 1. Hong RA, Licht JD, Wei JY, Heller GV, Blaustein AS, Pasternak RC. Elevated CKMB with normal total creatine kinase in suspected myocardial infarction: Associated clinical findings and early prognosis. Am Heart J 111:1041-1047, 1986.

2. Licht JD, Garnick MB: Phase II trial of strepozocin in the treatment of advanced renal cell carcinoma. Cancer Treat Rep 71:97-98, 1987.

3. Licht JD, Grossel MA, Figge J, Hansen UM. Drosophila Krüppel Protein is a Transcriptional Repressor. Nature 346:76-79, 1990.

4. Licht JD, Bosserman LD, Andersen JW, Yeap BY, Klatt MM, Martel JK, Anderson KC, Rosenthal DS, Pinkus G, Skarin AT, Canellos GP. Treatment of low and intermediate grade lymphoma with intensive chemotherapy leads to long term disease-free survival. Cancer 66:632-639, 1990.

5. Seiden MV, O'Donnell WJ, Weinblatt M, Licht JD. Vasculitis and recurrent pulmonary hemorrhage in a long term survivor after autologous transplantation for lymphoma. Bone Marrow Transplantation 6:345-347, 1990.

6. Licht JD, Gonin R, Antman KH. Phase II trial of trimetrexate in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 28:223-225, 1991.

7. DeFranco C, Ro M, Grossel M, Hansen UM, Wagner JA, Licht JD. NGF1A (EGR1) contains transcription activating domains in both the amino and carboxyl terminal regions of the protein. Biochem Bipohys Res Comm 194: 425-431, 1993.

8. Licht JD, Ro M, English MA, Grossel M, Hansen U. Selective repression of transcriptional activators at a distance by the Drosophila Krüppel protein. Proc Natl Acad Sci USA, 90: 11361-11365, 1993.

9. Licht JD, Hanna-Rose W, Reddy JC, English MA, Ro M, Grossel M, Shaknovich R, Hansen U. Mapping and mutagenesis of the amino terminal repression domain of the Drosophila Krüppel protein. Mol Cell Biol 14: 4057-4066, 1994.

10. Licht JD, Mazanet R, Loehrer, PJ, Gonin R, Antman K. Phase 4 trial of daily oral etoposide in the treatment of advanced soft tissue sarcoma. Cancer Chemother Pharmacol 34: 79-80, 1994.

11. Scott A, Head, DR, Kopecky KJ, Appelbaum FR, Theil KS, Grever MR, Chen I-M, Whitaker MH, Griffith BB, Licht JD, Waxman S, Whalen MM, Bankhurst AD, Richter LC, Grogan TM, Willman CL. HLA-Dr-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French- American British acute myeloid leukemia-M3. Blood 84:244-255, 1994.

12. Chen A, Licht JD, Wu Y, Hellinger N, Scher W and Waxman S. Retinoic acid is required for and potentiates superinduction of differentiation of acute promyelocytic leukemia cells by non- retinoid inducers. Blood 84: 2122-2129, 1994.

13. Licht JD, Chomienne C, Goy A, Chen A, Wu Y, Scott AA, Miller WH Jr., Zelenetz AD, Willman CL, Head DR, Chen Z, Chen S-J, Zelent A, Macintyre E, Veil A, Cortes J, Kantarjian H, Waxman S. Clinical and molecular characterization of a rare syndrome of acute promyleocytic leukemia associated with t(11;17) and fusion of the PLZF and RARα genes. Blood 85: 1083-1094. 1995.

14. Cook M, Gould A, Brand N, Davies J, Reid A, Strutt P, Shaknovich R, Licht J, Waxman S, Chen Z, Krumlauf R, Zelent A. Evolutionarily conserved expression of the leukemia translocation gene PLZF during neurogenesis and hemopoiesis. Proc Natl Acad Sci USA 92:2249, 1995.

15. Reddy JC, Morris J, Wang J, English MA, Haber DA, Shi Y, Licht JD. WT1-mediated transcriptional activation is inhibited by dominant-negative mutant proteins. J Biol Chem 270: 10878-10884, 1995.

16. Luo XN, Reddy JC, Levy PL, Haber DA, Licht JD, Atweh GH. The WT1 tumor supressor gene inhibits ras mediated growth and transformation. Oncogene 11: 743-750, 1995.

17. Reddy JC, Hosono S, Licht JD. The transcriptional effect of WT1 is modulated by choice of expression vector. J Biol Chem 270: 29976-29982, 1995.

18. Reid A, Gould A, Brand N, Cook M, Strutt P, Li J, Licht J, Waxman S, Krumlauf R, Zelent A. Leukemia tranlocation gene PLZF is expressed with a speckled nuclear pattern in early hematopoietic progenitor cells. Blood 86: 4544-4552, 1995.

19. Licht JD, Shaknovich R, Melnick A, English MA, Li J-Y, Reddy JC, Dong S, Chen S-J, Zelent A, Waxman S. Reduced and Altered DNA-Binding And Transcriptional Properties Of The PLZF-Retinoic Acid Receptor-α Chimera Generated In t(11;17)-Associated Acute Promyelocytic Leukemia. Oncogene 12:323-336, 1996

20. Duong S, Zhu J, Reid A, Strutt P, Guidez F, Zhong H-J, Wang Z-Y, Licht J, Waxman S, Chomienne C, Chen Z, Zelent A, Chen S-J. Amino-terminal protein-protein interaction motf (POZ domain) is responsible for the activites of promyelocytic leukemia associated PLZF-RARα fusion protein. Proc Natl Acad Sci USA 93:3624-3629, 1996.

21. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, Shi Y. A novel repressor par-4 modulates transcription and growth suppression functions of the Wilms' tumor suppressor, WT1. Molecular and Cellular Biology, 16:6945-6956, 1996.

22. Holmes G, Botahvelili S, English MA, Wainwright BJ, Licht JD, Little MH. Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash Mutant Proteins. Biochem Bipohys Res Comm, 233: 723-728, 1997.

23. Hanna-Rose W, Licht JD, Hansen U. Two evolutionarily conserved repression domains in the Drosophila Krüppel protein differ in activator specificity. Mol Cell Biol 17: 4820-4829, 1997.

24. Li JY, English, MA, Ball H, Yeyati PL, Waxman S, Licht JD. Sequence-specific DNA binding and transcriptional regulation by the Promyelocytic Leukemia Zinc Finger Protein. J Biol Chem 272: 22447-22455, 1997.

25. Somasundaram K, Zhang H, Zeng Y-X, Houvras Y, Wu GS, Peng Y, Zhang H, Licht JD, El-Deiry WS, Weber BL. BRCA1 inhibition of the cell cycle requires p21WAF1/CIP1. Nature 389: 187-190, 1997.

26. Koken MHM, Reid A, Quiquon F, Chebi-Alix MK, Davies JM, Kabarowski JHS, Zhu J, Dong S, Chen S-J, Chen Z, Tan CC, Licht JD, Waxman S, de Thé H, Zelent A. Leukemia-associated RARα fusion partners PML and PLZF heterodimerize and colocalize onto nuclear bodies. Proc Natl Acad Sci USA 94: 10255-10260, 1997.

27. Carroquino MJ, Galson SK, Licht J, Amler RW, Perera FP, Claxton LD, Landrigan PJ. The U.S. EPA Conference on Preventable Causes of Cancer in Children: A Research Agenda. Environ Health Perspect 106(Suppl 3):867-873, 1998

28. Shaknovich RS, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S, Zelent A, Licht JD. The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation and Apoptosis. Mol Cell Biol 18: 5533–5545, 1998.

29. Hosono S, Luo XL, Wilson PD, Burrow CR, Reddy, JC, Hyink DP, Schnapp LM, Atweh GH, Licht JD. WT1 expression induces features of renal differentiation in mesenchymal fibroblasts. Oncogene, 18: 417-427, 1999.

30. Hummel JL, Wells RA, Dubé ID, Licht JD, Kamel-Reid S. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Oncogene, 18: 633-642, 1999.

31. Yeyati PL, Shaknovich R, Ball HJ, Boterashvili S, Li J-Y, Waxman S, Zelent A, Licht JD. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 18:925-934, 1999.

32. Koken MHM, Daniel MT, Giannì M, Zelent A, Licht J, Degos L, Varet B, de Thé H. Retinoic Acid, but not Arsenic trioxide, degrades the PLZF/RARα fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17) APL patient. Oncogene 18: 1113-1118, 1999.

33. English, MA., Licht JD. Tumor-associated WT1 missense mutants indicate that transcriptional activation is essential for growth control. J Biol Chem 274: 13258-13263, 1999.

34. van Schothorst EM, Prins DEM, Baysal BE, Beekman M, Licht JD, Waxman S, Zelent A, Cornelisse CJ, van Ommen GJB, Richard III CW, Devilee P. Genomic structure of the human PLZF gene. Gene 236 21–24, 1999.

35. Ball H, Melnick A, Shaknovich R, Kohanski R, Licht JD. PLZF binds DNA as a high molecular weight complex in association with cell cycle regulatory proteins. Nucleic Acids Research 27: 4106-4113, 1999.

36. Zhang T, Xiong H, Kan L-X, Zhang C-K, Jia, X-F, Fu, G, Tong J-H, Gu B-W, Yu M, Licht J, Waxman S, Zellent A, Chen E, Chen S-J. Genomic sequence, structural organization, molecular evolution and aberrant rearrangement of the promyelocytic leukemia zinc finger gene. Proc Natl Acad Sci U S A. 96: 11422-11427, 1999

37. Melnick A; Fruchtman S; Zelent A; Liu M, Huang Q; Calasanz* MJ, Fernandez A, Licht JD, Najfeld V. Novel chromosomal rearrangements involving genetic loci usually associated with acute promyelocytic leukemia. Leukemia 13:1534-38, 1999.

38. Hoatlin ME, Zhi Y, Ball H, Silvey K, Melnick A, Stone S, Arai S, Hawe N, Owen G, Zelent A, Licht, JD. A novel BTB/POZ Transcriptional Repressor Protein Interacts With The Fanconi Anemia Group C Protein And PLZF- Blood. 94:3737-3747, 1999.

39. Melnick, A, Westendorf J, Pollinger A, Arai S, Ball H Hiebert SW, Licht JD. Functional and physical interaction between the PLZF and ETO proteins. Mol Cell Biol 20: 2075-2086, 2000.

40. Hosono S, Gross I, English MA, Hadja K, Fearon E, Licht JD. E-Cadherin is a WT1 target Gene. J Biol Chem 275:10943-10953, 2000.

41. Melnick A, Ahmad KF, Arai S, Polinger A, Ball H, Borden KL, Carlile GW, Privé GG, Licht JD. In Depth Mutational Analysis of the PLZF BTB/POZ Domain Reveals Motifs and Residues Required for Biological and Transcriptional Functions. Molecular and Cellular Biology, 20: 6550–6567, 2000.

42. Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW, Licht JD. The AML-1/ETO Fusion Protein is a Dominant Negative Inhibitor of Transcriptional Repression by PLZF. Blood. 96: 3939-47, 2000.

43. Houvras Y, Benezra, M., Zhang H, Manfredi JJ, Weber BL, Licht JD. BRCA1 Physically and Functionally Interacts with ATF1. J Biol Chem 275:36230-36237, 2000.

44. Srivastava DK, Tendler CL, Milani D, English MA, Licht JD, Wilson SH. The HIV-1 transactivator protein Tat is a potent inducer of the DNA repair enzyme ß-polymerase. AIDS 15:433-440, 2001

45. The acute promyelocytic leukemia associated protein, PLZF, inhibits 1,25(OH)2D3-induced monocytic differentiation of U937 cells through a physical interaction with VDR. Ward J, McConnell M, Carlile GW, Pandolfi PP, Licht JD, and Freedman LP. Blood, 98: 3290-3300, 2001.

46. Zhao F, Satoda M, Licht JD, Owa C, Gelb BD. Cloning and characterization of a novel mouse AP-2 transcription factor AP2δ, with unique DNA binding and transactivation properties. J Biol Chem 276:40755-40760, 2001.

47. Gross I, Bassit B, Benezra M, Licht, JD. Mammalian Sprouty Proteins Inhibit Cell Growth And Differentiation By Preventing Ras Activation- J Biol Chem 276: 46460–46468, 2001.

48. Melnick A, Carlile G, Ahmad KA, Kiang K Bardwell V, Prive GG, Licht JD. Critical Residues Within the BTB Domain of PLZF and Bcl6 Modulate Interaction with Co-Repressors. Mol and Cellular Biology 22:1804-1818, 2002.

49. Dai M-S, Chevallier N, Stone S, Heinrich MC, McConnell MJ, Reuter T, Broxmeyer HE, Licht JD, Li Lu L, Hoatlin ME. The effects of the Fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis and proliferation are differentiation-stage specific. J Biol Chem 277:26327-3, 2002.

50. Takahashi S, Licht JD. The human promyelocytic leukemia zinc finger gene is regulated by the Evi-1 oncoprotein and a novel guanine-rich site binding protein . Leukemia 16:1755-62, 2002.

51. McLoughlin P, Ehler E, Carlile G, Licht JD, Schäfer BW. The p53-inducible protein DRAL/FHL2 functionally interacts with the Promyelocytic Leukemia Zinc Finger protein. J Biol Chem. 277:37045-53, 2002

52. Labbaye C, Quaranta M, Pagliuca A, Militi S, Licht J, Testa U, Peschle C. PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA 1 protein Oncogene 21:6669-79, 2002

53. Schumacher V, Schuhen S, Sonner S, Weirich A, Leuschner I, Harm D, Licht J, Roberts S, Royer-Pokera B. Two molecular subgroups of Wilms tumors with or without WT1 mutations. Clinical Cancer Research 9:2005-14, 2003.

54. Benezra M, Chevallier N, Morrison DJ, MacLachlan TK, Wafik S. El-Deiry WS, Licht JD. BRCA1 augments transcription by the NF- B transcription factor by binding to the Rel domain of the p65/RelA subunit. J Biol Chem 278:26333-2641, 2003.

55. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, Hahlen K, Hasle H, Licht JD, Gelb BD. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 34:148-50, 2003

57. Gross I, Morrison D, Hyink DP, Georgas K, Milton A. English MA, Hosono S, Wilson PD, Little M, Licht JD. The Receptor Tyrosine Kinase Inhibitor Sprouty1 Is A Target Gene Of The Tumor Suppressor WT1 During Kidney Development. J. Biol. Chem. 278:41420-4143, 2003.

57. McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane J, Malani RB, Staudt LM, Licht JD. Growth Suppression by Acute Promyelocytic Leukemia-Associated Protein PLZF is Mediated by Repression of c-Myc Expression- Mol Cell Biol 24:9375-88, 2003.

58. Ahmad KF, Melnick A, Lax S, Bouchard D, Li J, Kiang C-L, Mayer S, Takahashi S, Licht JD, Privé GG. Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain. Molecular Cell 6:1551-64, 2003

59. Chevallier N, Corcoran C Lennon C, Bardwell V, Licht JD, Melnick A. ETO is a Co-Repressor for Bcl-6 in Both Normal and Malignant B-Lymphocytes. Blood 103:1454-63, 2004.

60. Mason JM, Morrison DJ, Bassit B, Dimri M, Band H, Licht JD, Gross I. Tyrosine phosphorylation of sprouty proteins stimulates their ability to inhibit growth factor signaling- a negative feed back loop. Molecular Biology of the Cell 15:2176-88, 2004.

61. Takahashi S, Harigae H, Kaku M, Sasaki T, Licht JD. Flt3 Mutation Activates p21WAF1/CIP1 Gene Expression Through the Action of STAT5- Biochem Biophys Res Commun 316:85-92, 2004.

62. Takahashi S, McConnell MJ, Harigae H, Mitsuo Kaku M Takeshi, Sasaki T, Melnick AM Licht JD. The Flt3 Internal Tandem Duplication Mutant Inhibits the Function of Transcriptional Repressors by Blocking Interactions with SMRT. Blood 103:4650-8, 2004.

63. Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF, Weber BL. BRAF mutations bypass SPRY-dependent negative feedback inhibition of MAPK pathway signaling. Cancer Research 64:5556-9, 2004.

64. Guo, G, Morrison DJ, Licht JD, Quaggin SE. WT1 Activates a Glomerular-Specific Enhancer Identified from the Human Nephrin Gene,. J Amer Soc Nephrol, 15 :2851-6, 2004.

65. Polo JM, Dell’Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick AA. Specific Peptide Interference Reveals Bcl-6 Transcriptional Mechanisms and Oncogenic Role in B-Cell Lymphoma. Nature Medicine, 10:1329-35, 2004.

66. Li C-M, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, Hensle TW, Murty VVVS, Grundy PE, Fearon E, D’Agati V, Licht JD, Tycko B. CTNNB1 mutations and over-expression of Wnt/beta-catenin target genes in WT1-mutant Wilms tumors. Amer J Path 6:1943-1953, 2004.

67. Olsson M, Mason JM, English MA, Licht JD, Ekblom P. WT1 binding sites in the promoter region of human and mouse nucleoporin 210, a marker for epithelial cells. J Negat Results Biomed. 3:7, 2004.

68. Basson MA, Akbulut S, Watson-Johnson J, Simon R, Carroll TJ, Shakya R, Gross I, Martin GR, Lufkin T, McMahon AP, Wilson PD, Costantini FD, Mason IJ, Licht JD. Sprouty1 Is A Critical Regulator Of GDNF/Ret-Mediated Kidney Induction-Developmental Cell 8:229-239, 2005.

69. Lin W, Jing N, Basson A, Licht J, Ang S-L. Synergistic activity of Sef and Sprouty proteins in regulating the expression of Gbx2 in the mid-hindbrain region- Genesis 41:110-115, 2005.

70. Guidez F, , Howell, L Isalan M, Cebrat M, Alani RM, Ivins, S, Hormaeche I, McConnell MJ, Pierce S, Cole PA, Licht J, Zelent A. Histone acetyltransferase activity of p300 is required for transcriptional repression by the Promyelocytic Leukemia Zinc Finger protein. Mol Cell Biol, 25:5552-66, 2005.

71. Takahashi S, Harigae H, Ishii KI, Inomata M, Fujiwara T, Yokoyama H, Ishizawa K, Kameoka J, Licht JD, Sasaki T, Kaku M. Over-expression of Flt3 induces NFB pathway and increases the expression of IL-6. Leukemia Research 29: 893-899, 2005.

72. Morrison DJ, English ME, Licht JD. WT1 induces apoptosis through transcriptional regulation of the pro-apoptotic Bcl-2 family member Bak. Cancer Research 65:8174-82, 2005.

73. Basson MA, Watson-Johnson J, Shakya R, Hyink D, Akbulut S, Costantini FD, Wilson PD, Mason IJ, Licht JD. Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1- Dev Biol 299:466-47, 2006

74. Bowler T, Kosman D, Licht JD, Pick L. Computational identification of Ftz/Ftz-F1 downstream target genes. Dev Biol 299:78-90, 2006.

75. Denne M, Sauter M, Armbruester V, Licht JD, Roemer K, Mueller-Lantzsch N. Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. J Virol. 81:5607-5616, 2007.

76. Gaiddon C, Armant O, Benosman S, Gonzales de Aguilar J-L, Freund JN, Kedinger M, Loeffler J-P, Licht JD and Gross I Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death and Differentiation 14:1802-12, 2007

77. Maekawa T, Sano Y, Shinagawa T, Rahman Z, Sakuma T, Nomura S, Licht JD, Ishii S. ATF-2 controls transcription of Maspin and GADD45alpha genes independently from p53 to suppress mammary tumors. Oncogene. 27:1045-54, 2008

78. Kim MKH, Mason JM, Li C-M, Berkofsky-Fessler W, Choubey D, Grundy PE, Tycko B, Licht JD. A Pathologic Link between Wilms Tumor Suppressor Gene, WT1, and IFI16. Neoplasia 10:69-78, 2008.

79. Marango J, Shimoyama M, Nishio H, Meyer JA, Min D-J, Sirulnik, Martinez- Martinez Y, Chesi M, Bergsagel PL, Zhou M-M, Waxman S, Leibovitch BA, Walsh MJ, Licht JD. The MMSET Protein is a Histone Methyltransferase with Characteristics of a Transcriptional Co-repressor. Blood, 111:3145-54, 2008.

80. Petrie K, Guidez F, Zhu J, Owen G, Chew YP, Waxman S, Licht J, Mitternach S, Zelent A. Retinoblastoma protein interacts with and enhances activity of the leukemia associated PLZF transcriptional repressor. Oncogene, 27:5260-6, 2008.

81. Morrison DJ, Kim MKH, Berkofsky-Fessler W, Licht JD. WT1 Induction of MKP3 Represents a Novel Mechanism of Growth Suppression. Molecular Cancer Research 7:1225-31, 2008

82. Polo JM, Ci W, Licht JD, Melnick A. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B-cells. Blood, 112:644-51, 2008

83. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456:980-4, 2008.

84. Wen Q, Leung C, Huang Z, Small S, Lakku Reddi A, Licht JD, Crispino JD. Survivin is not required for the endomitotic cell cycle of megakaryocytes. Blood 114:153-6, 2009.

85. Xu D, Holko M, Sadler AJ, Scott B, Higashiyama S, Berkofsky-Fessler W, McConnell MJ, Pandolfi PP, Licht JD, Williams BRG. Promyelocytic Leukemia Zinc Finger Protein Regulates Interferon-Mediated Innate Immunity. Immunity 30:802-16, 2009.

86. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell MJ, Nasrallah C, Kim MK, Zhang W, Sun Y, Murgo A, Espinoza-Delgado I, Oteiza K, Owoeye I, Silverman LR, Gore SD, Carraway HE. Reversal of Promoter Methylation is Not Required for Clinical Response in Patients with Myeloid Malignancies Receiving Therapy With Combination 5-azacitidine and Entinostat. Blood 114:2764-73, 2009

87. Kim MKH, McGarry TJ, Broin PO, Flatow JM, Golden AA-J, Licht JD. An Integrated Genome Screen Identifies The WNT Signaling Pathway As A Major Target Of WT1. Proc Natl Acad Sci USA 106:11154-9, 2009.

88. Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy T, Paietta E, Tallman MS, Greally JM Carraway H Licht JD, Gore SD, Melnick AM. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114:3448-58, 2009.

89. Chi X, Odyssé Michos O, Shakya R, Licht JD, Mendelsohn CL, Costantini F, Ret-dependent cell rearrangements in the Wolffian duct epithelium initiate ureteric bud morphogenesis. Dev Cell, 17:199-209, 2009

90. Doulatov S, Notta F, Rice KL, Howell L, Janmohamed S, Iscove N, Zelent A Licht JD, Dick JE. Identification of PLZF as a critical switch between human steady-state and cytokine-induced myelopoiesis- Genes Dev 23:2076-87, 2009.

91. Rice KL, Hormaeche, Doulatov, Flatow J, Grimwade D, Mills KI, Dick JE, Licht JD. Comprehensive Genomic Screens Identify a Role for PLZF-RARα as a Positive Regulator of Cell Proliferation via Direct Regulation of c-MYC. Blood 114:5499-511, 2009

92. Michos O, Hyink D, Grieshammer U, D’Agati V, Licht JD, Martin GR, Costantini F. Latent redundancy between Gdnf and Fgf10 during kidney development is revealed by loss of Sprouty1- I PLOS Genetics. Jan 15;6(1):e1000809, 2010

93. Shea KL, Wanyi Xiang W, LaPorta VS, Licht JD, Keller C, Basson MA, Andrew S. Brack AS. Sprouty1 regulates self-renewal of the adult muscle stem cell pool during regeneration. Cell Stem Cell 6 :117-129, 2010

94. Gilbert PM, Mouw JK, Unger MA, Lawkins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KKC, Welm AL, Feldman MD, Weber BL, Weaver V. HoxA9 regulates BRCA1 expression to modulate mammary tissue growth and survival- J Clin Invest. 120:1535-50, 2010.

95. Berkofsky-Fessler W, Buzzai M, Kim MKH, Fruchtman S, Najfeld V, Min DJ, Costa FF, Bischof JM, Soares MB, McConnell MJ, Zhang W, Levine R, Gilliland DG, Calogero R, Licht JD. Transcriptional Profiling Of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent And Independent From The Action Of JAK2V617F. Clinical Cancer Res 16: 4339-52, 2010

96. Akbulut S, Reddi AL, Ambardekar C, Canciani C, Kim MKH, Laura Hix L, Vilimas T, Mason J, Basson MA, Lovatt M, Powell J, Collins S, Quatela S, Phillips M, Licht JD. Sprouty Proteins Inhibit Receptor-Mediated Activation Of Phosphatidylinositol-Specific Phospholipase C. Mol Biol Cell, 21:3487-3496, 2010.

97. Kim, MKH, Min DJ, Rabin M, Licht JD. Characterization of Functional roles of Wilms Tumor Suppressor WTX and tumor associated WTX mutants. Oncogene 30:832-42, 2010

98. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell 8:553-67, 2010

99. Lagha M, Sato T, Regnault B, Cumano AD, Zuniga A, Licht J, Relaix F, Buckingham M. Transcriptome analyses based on genetic screens for Pax3 myogenic targets in the mouse embryo. BMC Genomics. 11:696, 2010.

100. Martinez-Garcia E, Popovic R, Min DJ, Sweet SMM, Thomas PM, Zamborg L, Heffner A, Will C, Lamy L, Staudt LM, Levens DL, Kelleher NL, Licht JD. The MMSET Histone Methyl Transferase Switches Global Histone Methylation and Alters Gene Expression in t(4;14) Multiple Myeloma Cells. Blood 117:211-20, 2011

101. Kuracha PR, Burgess D, Siefker E, Cooper J, Licht JD, Robinson, ML, Govindarajan V. Spry1 and Spry2 are necessary for lens and corneal differentiation. Investigative Ophthalmology & Visual Science. 52:6887-97, 2011

102. Rice KL, Lin, X, Ebert BL, Berkofsky-Fessler W, Buzzai M, Sun Y, Xi C, Elkin P , Levine RL, Golub T, Gilliland DG, Licht JD, Zhang W. Integrative analysis of genomic aberration and gene expression revealed a novel role of Jak2 V167F in gene expression regulations in Myeloproliferative Disorder. Blood Cancer J. 2011 1(11):e40. Epub 2011 Nov 11

103. Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian J-J, Levine RL, Licht JD, Mullally A, Odenike T, Pardanani A, Silver RT, Solary E, Mughal T. Mutations with putative epigenetic effect in myeloproliferative neoplasms and recent progress in prognostication and treatment: proceedings from the 5th international post-ASH symposium. Blood Cancer Journal (2011) 1, e7; doi:10.1038/bcj.2011.4

104. Biyashev D, Veliceasa D, Mizgirev I , Redd AL, Licht JD, Revskoy SY, Volpert OV. miRNA-27b promotes tip cell fate, sprouting and arterial-venous segregation by blocking Notch and Sprouty pathways. Blood. 119:2679-87, 2012

105. Sathyanarayana P, Dev A, Pradeep A, Licht JD, Wojchowski DM. Spry1 Acts As A Non-Redundant Regulator Of Erythropoiesis, Prime EpoR Target, And Novel Jak2 Suppressor- Blood. 119:5522-31, 2012

106. Hwangpo TA, Jordan D, Premsiriut P, Jayamaran G, Licht JD, Iyengar R, Neves SR. GRIN modulates Sprouty2 inhibitory effects on MAPK activation by growth factor stimulation- J Biol Chem. 287:13674-85, 2012.

107. Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Valk P, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vandewoude G, Licht JD, Kung AL, Staudt LM, Look AT. Aberrant expression of hepatocyte growth factor induces autocrine activation of MET, providing a novel therapeutic target in acute myeloid leukemia- Nat Med. 2012 Jun 10. doi: 10.1038/nm.2819

108. Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, Min DJ, Will CM, Neri A, Yu J, Kelleher NL, Licht JD. The Histone Methyl Transferase MMSET Activates TWIST1 to Promote an Epithelial-Mesenchymal Transition and Invasive Properties of Prostate Cancer- Oncogene. 2012 Jul 16. doi: 10.1038/onc.2012.297.

109. Zheng Y, Sweet SMM, Tipton JD, Popovic R, Martinez-Garcia E, Thomas PM, Licht JD, Kelleher NL. A Bidirectional Antagonism between Histone H3 Lysine 27 and 36 Determines Their Combinatorial Methylation Patterns in vivo. Proc Natl Acad Sci U S A. 109:13549-54, 2012.

110. Lin X, Rice KL, Buzzai M, Hexner E, Costa FF, Kilpivaara O, Mullally A, Soares MB, Ebert BL, Levine R, Licht JD. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia. 2012 Aug 6. doi: 10.1038/leu.

111. Min DJ, Ezponda T, Kim, MKH, Will CM , Martinez-Garcia E, Popovia R, Basrur V, Elentoba-Johnson K, Licht JD. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC- Leukemia. 2012 Sep 13. doi: 10.1038/leu.2012.269.

112. Collins SL, Waikman A, Basson MA, Licht JD, Horton MR, Powell JD. Regulation of CD4+ and CD8+ Effector responses by Sprouty-1. PLoS One. 2012;7(11):e49801. doi:.

113. Sharma B, Josh S, Sassano A, Majchrzak B, Kaur S, Aggarwal P, Nabet B, Bulic M, Stein BL, McMahon B, Baker DP, Fukunaga R, Altman JK, Licht JD, Fish N, Platanias LC. Sprouty proteins are negative regulators of interferon (IFN)-signaling and IFN-inducible biological responses- J Biol Chem. 287: 42352-60, 2012

114. Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, Wang C-R, Schumacker PT, Licht JD, Perlman H, Bryce PJ, Chandel NS. Mitochondria are required for antigen-specific T cell activation through ROS signaling. Immunity. 38:225-36, 2013.

115. Petruccelli LA, Pettersson F, del Rincon SV, Guilbert C, Licht JD, Miller Jr. WH. Expression of leukemia associated fusion proteins increases sensitivity to histone deacetylase inhibitor induced DNA damage and apoptosis. Mol Cancer Ther. 2013 Mar 27. [Epub ahead of print].

Invited Reviews

1. Licht JD, Weissman LB, Antman K. Gastrointestinal sarcomas. Sem Oncol 15: 181-188, 1988.

2. Reddy JC, Licht JD. The WT1 Wilms’ Tumor Supressor Gene: How Much Do We Really Know? BBA Reviews in Cancer 1287(1): 1-28, 1996.

3. Tenen DG, Hromas R, Licht JD, Zhang D-E. Transcription factors, normal myeloid development and Leukemia. Blood 90: 489-519, 1997.

4. Melnick A, Licht JD. Deconstructing a Disease: RARα, its fusion partners and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167-3215, 1999.

5. Licht JD AML1 and The AML1-ETO Fusion Protein In The Pathogenesis Of t(8;21) AML. Oncogene 20: 5560-5679, 2001.

6. Licht JD. Targeting Aberrant Transcriptional Repression: A Therapeutic reality? J Clinical Investigation, 108: 1277-1278, 2001.

7. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations Of The RARα Gene In Acute Promyelocytic Leukemia. Oncogene 20: 7186- 7203, 2001.

8. Melnick A, Licht JD. Histone Deacetylases as Therapeutic Targets in Hematological Malignancies. Current Opinion in Hematology 9: 322-332, 2002.

9. Gross I, Licht JD. Sprouty Proteins, A New Family of Receptor Tyrosine Kinase Inhibitors Current Genomics 3: 285-293, 2002.

10. Johnstone RW, Licht JD Histone Deacetylase Inhibitors In Cancer Therapy-Is the Transcription the target? Cancer Cell 2003 4:13-8, 2003.

11. Sirulnik A, Melnick A, Zelent A, Licht JD. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Pract Res Clin Haematol. 2003 16:387-408, 2003.

12. Sternberg DW, Licht JD. Therapeutic Intervention in Leukemias that Express the Activated FLT3 Tyrosine Kinase: Opportunities and Challenges- Current Opinion in Hematology, 12:7-13, 2005.

13. Licht JD, Zelent A. Retinoid and growth factor receptor signaling in APL. Blood 105:1381-2, 2005.

14. Melnick A, Adelson K, Licht JD. The Theoretical Basis of Transcriptional Therapy of Cancer: Can it be put into practice? J Clin Oncol 23: 3957-3970, 2005.

15. Sternberg DW, Licht JD. The Molecular Pathology of Acute Myeloid Leukemia. Hematology (Am Soc Hematol Educ Program). 2005:137-142, 2005.

16. Mason JM, Morrison, DJ, Basson MA, Licht JD. Sprouty Proteins: Multifaceted Negative Feedback Regulators Of Receptor Tyrosine Kinase Signaling. Trends Cell Biology 16: 45-54, 2006.

17. Licht JD. Reconstructing A Disease: What Essential Features Of The Retinoic Acid Receptor Fusion Oncoproteins Generate Acute Promyelocytic Leukemia? Cancer Cell 9: 73-74, 2006.

18. Licht JD. What Unleashes What Unleashes Aberrant Gene Regulation in APL? Blood 109:857, 2007.

19. Rice KL, Licht JD. HOX Gene Deregulation- A Common Theme in Acute Myelogenous Leukemia J Clin Invest. 117:865-868, 2007.

20. Hormache I, Licht JD. Chromatin Modulation by Oncogenic Transcription Factors-New Complexity, New Therapeutic Targets. Cancer Cell 6: 475-478, 2007.

21. Rice, KL, Hormache I, Licht JD. Epigenetic Regulation of Normal and Malignant Hematopoiesis. Oncogene 26: 6697-6714, 2007.

22. Frankfurt, O, Licht JD, Tallman MS. Molecular Characterization of Acute Myeloid Leukemia and its Impact in Treatment. Current Opinion in Oncology 19: 635-49, 2007.

23. Buzzai M, Licht JD. New Molecular Concepts and Targets in Acute Myeloid Leukemia- Current Opinion in Hematology, 15:82-87, 2008.

24. Licht JD. Acute Promyelocytic Leukemia and Weapons of Mass Differentiation. New Eng J Medicine 360:928-930, 2009.

25. Martinez-Garcia E, Licht JD. Deregulation of H3K27 Methylation in Cancer. Nat Genetics 42:100 101, 2010.

26. Min D-J, Licht JD. Partners In Crime: Genes Within An Amplicon Collude To Globally Deregulaton Chromatin in Lymphoma. Cancer Cell 18:539-41, 2010.

27. Popovic R, Licht JD. MM Flavors: Maf and MEK and Myeloma Therapy. Blood 117:2300-2302, 2011.

28. Shah MY, Licht JD. DNMT3A Mutations in AML. Nature Genetics, 29:289-90, 2011.

29. Shah MY, Licht JD. Epigenetics: What the Hematologist Should Know: The Hematologist, Spring, 2011.

30. Pettersson F, Miller WH Jr, Nervi C, Gronemeyer HJ, Licht J, Tallman MS, Waxman S. The 12th international conference on differentiation therapy: targeting the aberrant growth, differentiation and cell death programs of cancer cells. Cell Death Differ 18:1231-3, 2011

31. Popovic R, Licht JD. Emerging Epigenetic Therapies for Cancer, Cancer Discovery, 2: 405-13. 2012.

32. Khan I, Altman JK, Licht JD. New Strategies In Acute Myeloid Leukemia: Redefining Prognostic Markers To Guide Novel Therapies- Clin Cancer Res. 19: 5163-71, 2012

33. Beck S, Bernstein BE, Campbell RM, Costello JF, Dhanak D, Ecker JR, Greally JM, Issa JP, Laird PW, Polyak K, Tycko B, Jones PA; AACR Cancer Epigenome Task Force. A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. Cancer Res. 2012 Dec 15;72(24):6319-24

34. Popovic R, Shah MY, Licht JD Epigenetic therapy of hematological malignancies: where are we now? Ther Adv Hematol 4:81-91, 2013.

Book chapters:

1. Licht JD, Tsiftsoglou A. Mechanisms involved in the Differentiation of Leukemia. In: Proceedings of the Sixth Annual Conference on Differentiation therapy. Serono Symposium Publications, Rome. 1996.

2. Licht JD. Clinical and Molecular Characterization of t(11;17) APL and the role of the PLZF Gene. In: Proceedings of the Sixth Annual Conference on Differentiation therapy. Serono Symposium Publications, Rome. 1996.

3. Licht JD, Waxman S. The promyelocytic leukemia zinc finger gene. Encyclopedia of Molecular Medicine, John Wiley & Sons, 2002.

4. Privé GG, Melnick AM, Ahmad KF, Licht JD. The BTB Zinc Finger Proteins. In: Zinc Finger Proteins: from Atomic Contact to Cellular Function Editor: Iuchi S, Kuldell,N, Eds., Landes Bioscience, 2004.

5. McConnell MJ, Licht JD. The PLZF Protein. In- Acute Promyelocytic Leukemia. Pandolfi, PP Editor- Curr Top Microbiol Immunol. 313:31-48, 2007

Book Editing

K. Ravid, J.D. Licht- Transcription factors: Normal and malignant development of blood cells. John Wiley and Sons, 2001

Electronic Media

Alliance for Cellular Signaling/Nature Signaling Gateway

Gross I, Mason JM, Licht JD. Spry1 Full Molecule Page Published online: 18 Apr 2006 |doi:10.1038/mp.a002507.01

Mason JM, Gross I, Licht JD. Spry4 Full Molecule Page, Published online: 18 Apr 2006 |doi:10.1038/mp.a002507.01

Mason JM, Licht JD. Spry3 Full Molecule Page, Published online: 25 Feb 2005 |doi:10.1038/mp.a002509.01

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Martinez-Garcia E, Licht JD. WHSC1 (Wolf-Hirschhorn syndrome candidate 1). Atlas Genet Cytogenet Oncol Haematol. November 2008,

Personal tools